Lawrence Russell Smith, VP, Vaccine Research at VICAL INC (VICL), sold 4,500 shares at $2.26 ($10K) on 2017-02-10, disclosed to the SEC on 2017-02-14.
Scheduled sale ($10k) by VP, Vaccine Research under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| Filing → |
| VICL | SELL | 2016-10-12 | $165 | — | Filing → |
| VICL | SELL | 2016-07-13 | $241 | — | Filing → |
| VICL | SELL | 2016-03-17 | $4K | — | Filing → |